Bionano Genomics (BNGO) 10-K2022 FY Annual report

Filed: 9 Mar 23, 4:11pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigious
Readability	H.S. sophomore Avg

New words: agnostic, Aleksandar, attorney, band, BBC, Beach, bead, belonging, beta, Bio, bioprocessing, biotech, British, buffer, Canadian, Cantata, cardholder, cardiological, Carlo, CDPH, cellular, contradicted, corroborated, counter, cryptic, CV, degradation, dehydrated, denatured, deplete, drastically, DSS, duly, electrophoretically, ELN, embedded, EMEA, Euro, exacerbated, fewer, FFPE, fifteen, fined, fluid, formulated, fulsome, gentle, great, harvesting, hereof, hypoimmunogenic, hypothetical, ideal, ideally, inflation, inflationary, Inline, intact, invasion, Ionic, Irvine, ITP, Junior, lawfully, Leland, LeukemiaNet, lingering, Linkbase, Linney, Mazdan, misrepresentative, Monte, Nancy, native, newer, Novati, page, Paramit, password, path, PCI, Pleasanton, pluripotent, Pound, preserve, prognostic, prognostication, punitive, pure, purification, Purigen, purity, Qiagen, Rajkovic, relaxed, relocate, Renminbi, reopen, reopening, resubstitution, Ridge, scapula, Schema, scoring, sentiment, SFF, shoulder, signature, Simulation, SOC, souring, SP, Stanford, stead, SVTC, Taxonomy, Tesa, thereunder, thereunto, therewith, thing, tightening, turnover, UHMC, undersigned, unissued, variance, vast, Vincent, wash, wiretapping, Wong, worker, worsen, worsening, XBRL, Yvonne

Removed: absolute, accessible, accredited, assessed, Australian, biomedical, Boston, Canada, cancellation, Columbia, comprise, consecutive, conversion, crime, cut, deficiency, deletion, diagnose, Eastern, epidemic, exit, FSHD, Garvan, half, HMW, Hospital, importance, inflammatory, Institute, intervention, Iowa, McDonnell, mutation, nonrecurring, opening, opposition, outbreak, PerkinElmer, pervasive, Philadelphia, preempted, probe, prominent, promissory, promote, Radboud, remediated, Salk, school, segregation, separable, separation, sublease, substantive, Subtopic, suggesting, ultimate, unrestricted, Wall, Washington, willingly

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

Associated BNGO transcripts

BNGO similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.1

CERTIFICATION

Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the “Exchange Act”) and 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, R. Erik Holmlin, Chief Executive Officer of Bionano Genomics, Inc., a Delaware corporation (the “Company”), hereby certifies that, to the best of his knowledge:

1.The Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Annual Report”), and to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and

2.The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


Date: March 9, 2023

/s/ R. Erik Holmlin, Ph.D.
R. Erik Holmlin, Ph.D.

President and Chief Executive Officer (Principal Executive Officer)

This certification accompanies and is being “furnished” with this Annual Report, shall not be deemed “filed” by the Company for purposes of Section 18 of the Exchange Act, or otherwise subject to liability under that Section and shall not be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, whether made before or after the date of this Annual Report, irrespective of any general incorporation language contained in such filing.